https://scholars.lib.ntu.edu.tw/handle/123456789/633879
標題: | How should anti-hypertensive medications be adjusted before screening for primary aldosteronism? | 作者: | JIN-YING LU Chang, Yi-Yao Lee, Ting-Wei Wu, Ming-Hsien ZHENG-WEI CHEN Huang, Yen-Ta TAI-SHUAN LAI Er, Leay Kiaw YEN-HUNG LIN VIN-CENT WU Cheng, Hao-Min HSIEN-LI KAO Jia-Yin Hou, Charles KWAN-DUN WU Chen, Szu-Tah Liu, Feng-Hsuan |
關鍵字: | Aldosterone-to-renin ratio; Anti-hypertensive medications; Centrally acting α-adrenergic agonists; Nondihydropyridine calcium channel blockers; Primary aldosteronism; α-adrenergic receptor blocking agents | 公開日期: | 2024 | 卷: | 123 | 起(迄)頁: | S91 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633879 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2023.05.021 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。